Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...

With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...

Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth ...

Pfizer will cut over 200 jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on ...

Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist ...

After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...

Pfizer’s RIF and severance practices face scrutiny in a Dec. 8 New Jersey filing by a former physician challenging OWBPA ...

Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...

Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for ...

Pfizer said on Tuesday it entered into an exclusive licensing agreement with YaoPharma, a subsidiary of China's Shanghai ...

Fosun Pharmaceutical is a spinoff from Fosun International, which is chaired by China billionaire chairman Guo Guangchang; ...

Triana Biomedicines has tapped Pfizer Ventures and a number of other existing and new investors to secure a $120 million ...